

KS-V Peptide

Peptide Synthesis Service

www.ks-vpeptide.com



KS-V PEPTIDE
The Peptide Experts

About us


KS-V Peptide Biotechnology Co., Ltd. was founded in 2018 by three internationally renowned scientists from China University of Science and Technology, Tsinghua University, and Nankai University. Our company has several cutting-edge core technologies and four major platforms, including peptide synthesis platform, peptide drug discovery platform, structural biology platform, as well as pre-clinical testing platform. We can offer comprehensive support for integrated drug discovery and development services.

KS-V Peptide has provided peptide services to over 1,000 academic clients and 100 industrial clients from more than 30 countries. We are committed to promoting innovation to support drug research and development, as well as healthy living. At KS-V Peptide, we are excited to collaborate with clients around the world to create innovative partnerships.

Production Environment and Technology Platform

At KS-V Peptide, every peptide synthesis undergoes a rigorous quality control process, and the production environment and equipment are maintained and managed by dedicated personnel. Our strict operating procedures and management system ensure high-quality and efficient production of peptides.

With over 20 years of experience in peptide synthesis, we have advanced peptide synthesis instruments, professional team, and extensive expertise in peptide synthesis and purification processes. Our advanced peptide synthesis platform and quality control system work together to provide clients with high-quality products.



Peptide Synthesis Platform

Advanced Synthesis Technologies



- **Long peptide synthesis and refolding technology**

Total chemical synthesis of the longest (>400 AA) protein in the world, breaking the international record multiple times. It has been recognized in the field as “Powerful Advance” and “Method of Choice”.



- **Hydrophobic peptide synthesis and refolding technology**

Novel removable hydrophilic modification groups can increase the solubility of hydrophobic peptides. Combining with peptide linking technology, we achieve the total chemical synthesis of the largest (>130 AA) membrane protein in the world.



- **Peptide modification technology**

This involves common post-translational modifications of peptide synthesis, like phosphorylation and acetylation. Protein modifications such as ubiquitins can also be synthesized. Other modifications include fluorescence labeling, bioorthogonal handles, short and long-chain PEG, DOTA labeling, palmitoylation, and other lipid modifications. All-D amino acid-containing peptides and proteins can be prepared.



- **Unnatural amino acid module library**

Having a large library of non-natural amino acid modules, the introduction of non-natural amino acids can improve the activity and pharmacokinetic stability of peptides. The non-natural amino acid molecular library can be used for the synthesis of active cyclic peptides and for exploring structure-activity relationships.



- **Peptide conjugation technology**

We have innovatively overcome the compatibility issue between peptide and DNA solid-phase synthesis, achieving efficient one-step solid-phase synthesis of peptide-DNA conjugates. The sequences and linker for conjugation can be customized as desired, enabling high-throughput construction of peptide-DNA libraries. We also have the technology for developing novel peptide-drug conjugates (PDCs).




- **Peptide cyclization technology**

Our advanced peptide cyclization technology enables the creation of large cyclic and polycyclic peptides with unique structures, high connectivity, and distinctive topological properties. These novel peptides can offer enhanced stability and bioactivity, making them attractive candidates for drug development and research tools. With our platform, we can help you design and synthesize custom cyclic and polycyclic peptides tailored to your specific needs and research goals.

Quality Control & Quality Assurance

Every peptide synthesized at KS-V Peptide undergoes a rigorous quality control process. Our comprehensive quality control management platform requires each peptide to undergo three rounds of reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry (MS) analysis during synthesis, purification, and QC to ensure the quality of every peptide. KS-V Peptide also conducts additional QA rechecks to further ensure high-quality peptide delivery.



KS-V Peptide's comprehensive quality control management platform for peptide synthesis service

Regular and Express Peptide Synthesis

KS-V Peptide is committed to innovative technology development and exploring new techniques for peptide synthesis. We have provided over 30,000 high-quality peptides to more than 3,000 scientists globally. Using our independently developed advanced microwave technology for peptide synthesis, KS-V Peptide can deliver peptides in as short as 3 days. Our strict QC testing service ensures that every peptide is delivered at a high level of quality.

Service Features



100% guaranteed quantity

Avoid quantity risk



As fast as 3 days
Accelerate research



Comprehensive QC/QA system

Triple MS/HPLC detection



Batch to batch stability

Mature packaging system

Custom Peptide Service

	Regular Peptide Synthesis	Fast Peptide Synthesis	Rush Peptide Synthesis
Delivery Time* (Business Days)	10	6	3
Sequence Length	Up to 400AA	5-25AA	5-25AA
Purity	Crude to $\geq 98\%$	Crude to $\geq 98\%$	Crude
Quantity	mg ~ kg	1-100 mg	1-100 mg
Modifications	>400 modifications	30 modifications	30 modifications
Solubility Testing	√	√	X
TFA Counter-ion removal	Guaranteed and Standard	Standard	Standard

* Delivery times are for standard sequences only. Difficult sequences, sequences with multiple modifications or additional QC may require additional time.

** 100% guaranteed maximum quantity delivery for peptides in quantity less than 20 mg.

*** Express Peptide Synthesis Service includes Fast and Rush Peptide Synthesis Services.

Delivery Standard

We delivery peptides in lyophilized powder form, packaged in separate sample vials according to customer requirements. To ensure peptide quality, KS-V Peptide also provides the following documents and services.

HPLC/MS testing report

Certificate of Analysis (COA)

Technical consulting support

Flexible packaging options

Peptide Library Services

KS-V Peptide offers a variety of peptide library synthesis services, which can be applied in the fields of structural biology, peptide drug development, and vaccine development. Based on advanced library synthesis technology, KS-V's peptide synthesis capacity can reach up to 10,000 peptides per month, fully satisfying the increasing demand for peptides. In addition, there are professional peptide library design tools available to assist in designing seven types of peptide libraries, including overlapping peptide libraries.



- ✓ **High throughput:** 10,000 peptides/month.
- ✓ **Reliable quality:** precise controls and fully automated production pipeline.
- ✓ **Fast turnaround time.**
- ✓ **Flexible services:** regular peptide library services + additional QC + custom service per client needs.

Service Specifications

	Crude peptide library	Purified peptide library
Length	5-25AA	5-25AA
Purity	Crude peptide	≥70% to ≥98%
Scale	1-20 mg	1-9 mg
Turnaround time*	2-3 weeks	2-3 weeks
Minimum library size	30 peptides	30 peptides
Product form**	Lyophilized peptides in 96-well plates or tube racks	
Quality documents	MS only, or COA, HPLC and MS	COA, HPLC and MS
Modifications	Phosphorylation, Acylation, acetylation, biotination; fluorescence tags, stable isotope labelling; unnatural amino acids.	

* Longer turnaround time for peptide library with more than 60 peptides

** Peptide pool available per requirement.

Free Peptide Library Design

We provide free peptide library design tools. For different downstream applications, Our expert team would be happy to provide design guidelines.

Large-Scale Peptide Synthesis

Large-scale peptide production (in the kg or above range) finds extensive applications in peptide drug development, food research, and cosmetics. In large-scale peptide synthesis, it is not simply a matter of adding more raw materials, but also involves a series of improvements in process optimization and parameter adjustment to ensure the final product is delivered economically and efficiently.

With over 20 years of experience in peptide synthesis, KS-V Peptide has independently developed a multi-channel platform for large-scale peptide synthesis, which can efficiently produce kilogram-scale or larger quantities of peptides. Multiple QC testing ensure the quality of the final product.

Service Features



Up to 1 kg monthly production capacity



Over 98% success rate



Designated project manager



Cost-efficient synthesis and fast delivery

Service Specifications

Standard services		Customized services (optional)
Purity	≥98%	Process optimization Sample trial Customized analytical testing Analytical method development Parameter identification reports R&D reports Product reports Customized packaging and delivery
Quantity	Up to 1kg	
Length	Up to 100 AA	
Deliverable Format	Lyophilized powder	
Quality Documents	COA、 HPLC and MS	
Project management	Designated project manager	

Applications



Peptide drug development



API



Antimicrobial peptides

QC Services

At KS-V Peptide, all peptide synthesis undergoes comprehensive quality control, which includes MS and HPLC analysis. In addition, to meet the specific needs of different experiments, we also provide the following QC testing services:

- Solubility testing
- Amino acid analysis
- Moisture content analysis
- Polarimetric analysis
- PH testing
- TFA Counter-ion removal
- Peptide content/Nitrogen elemental analysis
- Stability testing
- Amino acid sequencing
- Endotoxin control & analysis
- Antagonistic ion quantification testing
- HPLC-UV-Fluorescence detection

◆ Solubility Testing Service

Solubility testing provides a reference for better dissolution of peptides, especially for hydrophobic peptides. We provide complete and tailored report on the solubility characteristics of the peptide to save your time and peptide sample. You can request the solubility test with the solvent of your choice. Below is an example:

Solvent	Result	Gross peptide concentration
Ultrapure water	Soluble	≤10mg/ml
1 xDPBS (pH 7.4 ± 0.1)	Soluble	≤10mg/ml
DMSO	Soluble	≥10mg/ml
Other solvent(s)	N/A	N/A

◆ Endotoxin Analysis and Control

To minimize the impact of endotoxins on your experiments, We provide endotoxin control services. We ensure the endotoxin level below 0.01 EU/μg.

Service	Endotoxin level	Turnaround time	Report
Endotoxin analysis	-	2 business days	Yes
Endotoxin control	< 0.01EU/μg	2 business days	Yes

*Endotoxin control service only applies to regular and fast peptide synthesis services.

◆ TFA Removal Service

Custom peptides may contain 10-45% TFA, which can lead to unpredictable fluctuations in in vitro and in vivo experiments. We provide TFA removal services using our unique reverse charge ion exchange technology, replacing TFA with acetate, formate or chloride

Service	Residual TFA	Report	Turnaround time
Standard	<10%	Optional	2 business days
Guaranteed	<1%	Default	8 business days

Peptide Modification Service

Appropriate modifications of peptides can greatly enhance their efficacy and broaden their scope of applications. Peptide modification, as an important means of altering the main chain structure or side chain functional groups of peptides, can effectively change the physicochemical properties, improve water solubility, reduce toxicity and side effects, and extend half-life.

We offer various types of peptide modifications, including but not limited to the following categories. Visit our website: www.ks-vpeptide.com for more info.

Acetylation and Acylation	Biotin and FITC labeling	Peptide cyclization
Phosphorylation	Methylation	KLH, BSA, OVA
PEGylation	Isotopic labeling	Multiple Antigenic Peptides

- **Acetylation and Acylation**

Peptide N-terminal acetylation or C-terminal amidation simulates protein natural enhance the resistance of the peptide to endopeptidases.

- **Biotin and FITC labeling**

Fluorescence labeling/biotinylation

- **Peptide cyclization**

We offer cyclization services including disulfide bond/amide bond cyclization, etc. Cyclization types include N- and C-terminal cyclization, side chain cyclization, and bicyclization.

- **Phosphorylation**

Phosphorylation of peptides can help study the effects of phosphorylation on peptide and protein structure, as well as the mechanism of protein kinases. We offer phosphorylated peptide synthesis with phosphorylated serine, threonine, and tyrosine peptides.

- **Methylation**

Protein methylation helps regulate cellular functions such as transcription, cell division, and cell differentiation.

- **KLH, BSA, OVA**

Conjugation antigenic peptides on KLH/BSA/OVA proteins for enhanced immune response

- **PEGylation**

PEGylation can enhance peptide water solubility/stability, reduce systemic toxicity/immunogenicity, and improve pharmacokinetics.

- **Isotopic labeling**

^2H 、 ^{15}N 、 ^{13}C or $^{15}\text{N}/^{13}\text{C}$ co-labeling for NMR analyses.

- **Multiple antigenic peptide (MAP)**

MAPs are dendritic peptides with multiple copies of antigenic peptides formed with lysine α -/ ϵ -amines. It has enhanced immunogenicity and high stability.

KS-V peptide

Catalog peptides

List of Catalog Peptides

◆ Ubiquitin and Ubiquitin probes

Cat. No.	Product Name	Quantity	Purity	Price
U1000	Ubiquitin	1 mg	≥95%	\$111
U1010	Ub-AMC	50 µg	≥95%	\$126
U2101	Met1-Diubiquitin	50 µg	≥95%	\$75
U2201	K6-Diubiquitin	50 µg	≥95%	\$111
U2301	K11-Diubiquitin	50 µg	≥95%	\$111
U2401	K27-Diubiquitin	50 µg	≥95%	\$111
U2501	K29-Diubiquitin	50 µg	≥95%	\$111
U2601	K33-Diubiquitin	50 µg	≥95%	\$111
U2701	K48-Diubiquitin	50 µg	≥95%	\$132
U2801	K63-Diubiquitin	50 µg	≥95%	\$132
U1020	Ub-ACC	50 µg	≥95%	\$277
U1030	Ub-Rho110	50 µg	≥95%	\$226
U1040	Ub-Prg	50 µg	≥95%	\$236
U1050	Ub-Br2	50 µg	≥95%	\$241
UD2201	Dha-K6-Diubiquitin	50 µg	≥95%	\$249
UD2301	Dha-K11-Diubiquitin	50 µg	≥95%	\$249
UD2401	Dha-K27-Diubiquitin	50 µg	≥95%	\$249
UD2501	Dha-K29-Diubiquitin	50 µg	≥95%	\$249
UD2601	Dha-K33-Diubiquitin	50 µg	≥95%	\$249
UD2701	Dha-K48-Diubiquitin	50 µg	≥95%	\$259
UD2801	Dha-K63-Diubiquitin	50 µg	≥95%	\$259

◆ Histone and Modified histone

Cat. No.	Product Name	Quantity	Purity	Price
H1200	H1	50 µg	≥ 95%	\$84
H1201	H1.2	50 µg	≥ 95%	\$122
H1300	H2A	50 µg	≥ 95%	\$84
H1301	H2A-Y57ph	50 µg	≥ 95%	\$799
H1302	H2A-S96ph	50 µg	≥ 95%	\$799
H1401	H2A-K13Ub	50 µg	≥ 95%	\$885
H1402	H2A-K15Ub	50 µg	≥ 95%	\$885
H1403	H2A-K119Ub	50 µg	≥ 95%	\$885
H1404	H2A.ZK121Ub	50 µg	≥ 95%	\$885
H2300	H2B	50 µg	≥ 95%	\$84
H2301	H2B-S14ph	50 µg	≥ 95%	\$799
H2401	H2B-K34Ub	50 µg	≥ 95%	\$885
H2402	H2B-K120Ub	50 µg	≥ 95%	\$885
H3100	H3	50 µg	≥ 95%	\$84
H3101	H3-K4me1	50 µg	≥ 95%	\$1,056
H3102	H3-K4me2	50 µg	≥ 95%	\$1,141
H3103	H3-K4me3	50 µg	≥ 95%	\$1,056
H3104	H3-K9me1	50 µg	≥ 95%	\$1,056
H3105	H3-K9me2	50 µg	≥ 95%	\$1,141
H3106	H3-K9me3	50 µg	≥ 95%	\$1,056
H3107	H3-K27me1	50 µg	≥ 95%	\$1,056
H3108	H3-K27me2	50 µg	≥ 95%	\$1,141
H3109	H3-K27me3	50 µg	≥ 95%	\$1,056
H3110	H3-K36me1	50 µg	≥ 95%	\$1,056
H3111	H3-K36me2	50 µg	≥ 95%	\$1,141
H3112	H3-K36me3	50 µg	≥ 95%	\$1,056
H3113	H3-R42me2a	50 µg	≥ 95%	\$1,234
H3114	H3-K79me2	50 µg	≥ 95%	\$1,373
H3202	H3-K18ac	50 µg	≥ 95%	\$1,056
H3201	H3-K56ac	50 µg	≥ 95%	\$1,141
H3203	H3-K64ac	50 µg	≥ 95%	\$1,141
H3204	H3-K122ac	50 µg	≥ 95%	\$1,056
H3301	H3-S10ph	50 µg	≥ 95%	\$1,109
H3302	H3-T118ph	50 µg	≥ 95%	\$1,109
H4100	H4	50 µg	≥ 95%	\$84
H4101	H4-K20me2	50 µg	≥ 95%	\$961
H4201	H4-K8ac	50 µg	≥ 95%	\$926
H4202	H4-K12ac	50 µg	≥ 95%	\$926
H4203	H4-K16ac	50 µg	≥ 95%	\$926
H4204	H4-K20ac	50 µg	≥ 95%	\$926
H4205	H4-K5ac	50 µg	≥ 95%	\$926
C16314	CENPA-S17ph	50 µg	≥ 95%	\$1,045
C16368	CENPA-S68ph	50 µg	≥ 95%	\$1,045

◆ Toxin peptides

Cat. No.	Product Name	Quantity	Purity	Price
C1010-V	Calciseptine	50 µg	≥95%	\$225
C1020-V	Calcicludeine	50 µg	≥95%	\$204
C1030-V	ω-conotoxin GVIA	50 µg	≥95%	\$86
C1040-V	ω-conotoxin MVIIA	50 µg	≥95%	\$129
C1050-V	ω-agatoxin IVA	50 µg	≥95%	\$214
C1060-V	ω-agatoxin IVB	50 µg	≥95%	\$236
C1080-V	SNX482	50 µg	≥95%	\$246
C1090-V	kurtoxin	50 µg	≥95%	\$611
C1100-V	PLTX-II	50 µg	≥95%	\$525
N1010-V	μ-conotoxin GVIA	50 µg	≥95%	\$118
N1020-V	huwentoxin IV	50 µg	≥95%	\$182
N1030-V	Protoxin II	50 µg	≥95%	\$139
K1010-V	ShK Toxin	50 µg	≥95%	\$96
K1020-V	Margatoxin	50 µg	≥95%	\$161
K1030-V	Dendrotoxin-I	50 µg	≥95%	\$354
K1060-V	Iberiotoxin	50 µg	≥95%	\$139
K1070-V	Kaliotoxin	50 µg	≥95%	\$210
K1080-V	Charybdotoxin	50 µg	≥95%	\$139
K1090-V	Apamin	50 µg	≥95%	\$75
K1100-V	Leiurotoxin I	50 µg	≥95%	\$139
K1110-V	GxTx-1E	50 µg	≥95%	\$171
K1120-V	Tertiapin-Q	50 µg	≥95%	\$139
O1010-V	Mambalgin-1	50 µg	≥95%	\$182
O1020-V	Mambalgin-2	50 µg	≥95%	\$182
O1030-V	Mambalgin-3	50 µg	≥95%	\$182
O1040-V	APETx2	50 µg	≥95%	\$161
O1050-V	α-conotoxin GI	50 µg	≥95%	\$96
O1060-V	α-conotoxin Iml	50 µg	≥95%	\$96
O1070-V	α-conotoxin MI	50 µg	≥95%	\$96
O1080-V	GsMTx-4	50 µg	≥95%	\$139
O1090-V	Muscarinic toxin 1	50 µg	≥95%	\$257
O1100-V	Muscarinic toxin 3	50 µg	≥95%	\$257
O1110-V	Muscarinic toxin 7	50 µg	≥95%	\$257
O1120-V	Psalmotoxin 1	50 µg	≥95%	\$161
KS201001	Mastoparan	1 mg	≥95%	\$48

◆ Peptide Drug Development

Diabetes related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS033001	Glucagon (human)	HSQGTFSTSDYSKYLDSRRAQDFVQ WLMNT-OH (trifluoroacetate salt)	16941-32-5	\$239	≥95%
KS032002	GLP-1 (1-37) (human)	HDEFERHAEGTFTSDVSSYLEGQAA KEFIAWLVKGRG-OH (trifluoroacetate salt)	87805-34-3	\$304	≥95%
KS031003	Proinsulin C-Peptide (55-89) (human)	RREAEDLQVGQVELGGGPGAGSL QPLALEGSLQKR-OH	11097-48-6	\$288	≥95%
KS031004	Exendin-4; Exenatide	HGEGTFTSDLKQMEEEAVRLFIEWL KNGGPSSGAPPPS-NH2	141758-74-9	\$321	≥95%
KS032005	Amylin (human)	KCNTATCATQRLANFLVHSSNFG AIISSNVGSNTY-OH (trifluoroacetate salt) (Cys2 and 7 bridge)	122384-88-7	\$366	≥95%
KS031006	C-Peptide (human); Insulin Precursor (57-87) (human)	EAEDLQVGQVELGGGPGAGSLQ PLALEGSLQ-OH (trifluoroacetate salt)	33017-11-7	\$255	≥95%
KS031007	Oxyntomodulin (porcine, bovine)	HSQGTFSTSDYSKYLDSRRAQDFVQ WLMNTRKRNKNNIA-OH (trifluoroacetate salt)	74870-06-7	\$304	≥95%
KS032008	GLP-2 (1-33) (human)	HADGSFSDEMNTILDNLAARDFINW LIQTKITD-OH (trifluoroacetate salt)	223460-79-5	\$272	≥95%
KS032009	GLP-2 (1-34) (human)	HADGSFSDEMNTILDNLAARDFINW LIQTKITDR-OH (trifluoroacetate salt)	99120-49-7	\$280	≥95%
KS032010	GLP-1 (1-36) amide (human)	HDEFERHAEGTFTSDVSSYLEGQAA KEFIAWLVKGR-NH2 (trifluoroacetate salt)	99658-04-5	\$297	≥95%
KS031011	IGF-I Analog	CYAAPLPAKSC-OH (trifluoroacetate salt) (Disulfide bond)	147819-32-7	\$146	≥95%
KS032012	Amylin (rat)	KCNTATCATQRLANFLVRSSNNLGP VLPPTNVGSNTY-NH2 (trifluoroacetate salt) (Cys2 and 7 bridge)	124447-81-0	\$457	≥95%
KS031013	Exendin-4 (9-39)	DLSKQMEEEAVRLFIEWLKNGGPSS GAPPPS-NH2 (trifluoroacetate salt)	133514-43-9	\$255	≥95%
KS031014	GLP-2 (rat)	HADGSFSDEMNTILDNLATRDFINWL IQTKITD-OH (trifluoroacetate salt)	195262-56-7	\$272	≥95%

◆ Peptide Drug Development

Alzheimer's Disease related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS011001	Apolipoprotein B Synthetic Peptide	KYYELEEKIVSLIKNLLVALK-OH (trifluoroacetate salt)		\$162	≥95%
KS011002	β-Amyloid (1-42) (human)	DAEFRHDSGYEVHHQKLVFF AlaGluAspValGlySerAsnLysGlyAla alleleGlyLeuMetValGlyGlyValVal IleAlaOH	107761-42-2	\$444	≥95%
KS011003	β-Amyloid (1-40) (human)	DAEFRHDSGYEVHHQKLVFFAEDV GSNKGAIIGLMVGGVV (trifluoroacetate salt)	131438-79-4	\$329	≥95%
KS012004	β-Secretase Substrate I (MCA-DNP pair)	(MCA)EVKMDAEFK(DNP)-NH2 (ammonium acetate salt)		\$219	≥95%
KS012005	α-Secretase Substrate I (MCA-DNP pair)	(MCA)HQKLVFFAK(DNP)NH2 (trifluoroacetate salt)		\$219	≥95%
KS011006	β-Amyloid (25-35) (human)	GSNKGAIIGLM-OH (trifluoroacetate salt)	131602-53-4	\$66	≥95%
KS011007	Galanin (human)	GWTLNAGYLLGPHAVGNHRFSFD KNGLTS-OH (trifluoroacetate salt)	119418-04-1	\$247	≥95%
KS011008	Humanin (human)	MAPRGFSCLLLTSEIDLPKRRA- OH (trifluoroacetate salt)	330936-69-1	\$146	≥95%
KS011009	Galanin (1-13)-Pro- Pro-(Ala-Leu) ₂ -Ala amide	GWTLNAGYLLGPPPALALA-NH2 (trifluoroacetate salt)	143896-17-7	\$118	≥95%
KS011010	Galanin (rat)	GWTLNAGYLLGPHAIDNHRFSFDK HGLT-NH2 (trifluoroacetate salt)	114547-31-8	\$239	≥95%

Multiple sclerosis related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS161001	Myelin Oligodendrocyte Glycoprotein (35-55) (rat)	MEVGWYRSPFSRVVHLYRNGK -OH	149635-73-4	\$124	≥95%
KS161002	Myelin Oligodendrocyte Glycoprotein (35-55) (human)	MEVGWYRPPFSRVVHLYRNGK -OH (trifluoroacetate salt)	163158-19-8	\$124	≥95%

◆ Peptide Drug Development

Antimicrobial related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS021001	Influenza Hemagglutinin (HA) Peptide	YPYDVPDYA-OH (trifluoroacetate salt)	92000-76-5	\$55	≥95%
KS021002	LL-37	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLLVPRTES-OH (trifluoroacetate salt)	154947-66-7	\$304	≥95%
KS022003	Fusion Inhibitory Peptide	ZfFG-OH	75539-79-6	\$40	≥95%
KS022004	Malaria Aspartyl Proteinase FRET Substrate (Dabcyl-Edans pair)	DABCYL-ER(Nle)FLSFPE(DANS) (trifluoroacetate salt)	263718-22-5	\$255	≥95%
KS021005	Leupeptin	Ac-LLR-CHO (trifluoroacetate salt)	103476-89-7	\$22	≥95%
KS021006	Defensin HNP-3 (human)	AFTCHCRRSCYSTEYSYGTCTVMGINHRF CCL-OH (trifluoroacetate salt) (Cys4 and Cys31/Cys6 and Cys20/Cys10 and Cys30 Disulfide Bridges)	136661-76-2	\$765	≥95%
KS021007	HIV (GP120) Antigenic Peptide	CGKIEPLGVAPTAKRRVQREKR-OH (trifluoroacetate salt)	198636-94-1	\$146	≥95%
KS021008	HIV-1 TAT Protein (47-57)	YGRKKRRQRRR-OH (trifluoroacetate salt)	191936-91-1	\$66	≥95%
KS021009	CRAMP (mouse)	GLLRKGGEKIGELKKIGQKIKNFFQKLVPQPEQ-OH (trifluoroacetate salt)	376364-36-2	\$200	≥95%
KS021010	β-Defensin-2 (human)	GIGDPVTCLKSGAICHVPFCPRRYKQIGT CGLPGTKCCKP-OH (trifluoroacetate salt) (Cys8 and 37 bridge, Cys20 and 38 bridge, Cys15 and 30 bridge)	372146-20-8	\$1,333	≥95%
KS021011	Apelin (1-13) (human)	QRPRLSHGKMPMPF-OH (trifluoroacetate salt)	217082-58-1	\$77	≥95%
KS021012	Histatin 5	DSHAKRHHGYKRKFHEKHSHRGY-OH (trifluoroacetate salt)	104339-66-4	\$146	≥95%
KS021013	HIV (gp41) Fragment	AVGIGA-OH (trifluoroacetate salt)	129426-47-7	\$36	≥95%
KS021014	β-Defensin-1 (human)	DHYNVCVSSGGQCLYSACPIFTKIQTGTCYR GKAKCCK-OH (trifluoroacetate salt) (Cys5 and 34 bridge, Cys12 and 27 bridge, Cys17 and 35 bridge)		\$889	≥95%
KS021015	Cecropin B	KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL-NH2 (trifluoroacetate salt)	80451-05-4	\$288	≥95%

◆ Peptide Drug Development

Gastrointestinal Disease related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS042001	Somatostatin 14	AGCKNFFWKTFTSC-OH (Disulfide Bridge)	38916-34-6	\$164	≥95%
KS042002	Octreotide	fCFwKTCT-ol (Disulfide Bridge)	79517-01-4	\$164	≥95%
KS041003	GIP (human)	YAEGTFISDYSIAMDKIHQQDFVN WLLAQKGGKNDWKHNITQ-OH	10040-31-1	\$444	≥95%
KS042004	Peptide YY (canine, mouse, porcine, rat)	YPAKPEAPGEDASPEELSRYYASLR HYLNLVTRQRY-NH2 (trifluoroacetate salt)	81858-94-8	\$297	≥95%
KS042005	Peptide YY (human)	YPIKPEAPGEDASPEELNRYASLR HYLNLVTRQRTY-NH2 (trifluoroacetate salt)	118997-30-1	\$297	≥95%
KS042006	Gastrin 1 (human)	Glp-GPWLEEEEEAYGWMDf-NH2	10047-33-3	\$100	≥95%
KS042007	Caerulein	Glp-QDY(SO3H)TGWMDf-NH2	17650-98-5	\$71	≥95%
KS042008	Secretin (porcine)	HSDGTFTSELSRLRDSARLQRLQGG LV-NH2 (acetate salt)	17034-34-3	\$222	≥95%
KS042009	Gastrin-Releasing Peptide (human)	VPLPAGGGTVLTKMYPRGNHWA VGHLM-NH2 (trifluoroacetate salt)	93755-85-2	\$222	≥95%
KS041010	VIP receptor antagonist (Human, Bovine, Porcine, Rat)	HSDAVf(4- Cl)TDNYTRLRKLAVKKYLNLSILNN H2 (trifluoroacetate salt)	102805-45-8	\$231	≥95%
KS042011	DOTA-[Tyr3]- Octreotide	DOTA-fCYwKTCT-ol (trifluoroacetate salt) (Cys2 and 7 bridge)	177943-89-4	\$528	≥95%
KS042012	Secretin (human)	HSDGTFTSELSRLREGARLQRLQGG LV-NH2 (trifluoroacetate salt)	108153-74-8	\$222	≥95%
KS042013	Insulin B (13 – 23)	HGluAlaLeuTyrLeuValCysGlyGlu ArgGlyOH (ammonium salt)		\$87	≥95%
KS042014	Motilin (human, Porcine)	FVPIFTYGELQRMQEKERNKGQ- OH (trifluoroacetate salt)	9072-41-7	\$129	≥95%
KS041015	Pancreatic Polypeptide (rat)	APLEPMYPGDYATHEQRAQYETQ LRRYINTLTPRY-NH2 (trifluoroacetate salt)	90419-12-8	\$304	≥95%
KS041016	PHI-27 (rat)	HADGVFTSDYSRLLGQISAKKYLE LI-NH2 (trifluoroacetate salt)	96849-38-6	\$222	≥95%
KS041017	Uroguanylin (human)	HAsnAspAspCysGluLeuCysValA snValAlaCysThrGlyCysLeuOH (Cys4 and 12 bridge, Cys7 and 15 bridge)	152175-68-3	\$95	≥95%

◆ Peptide Drug Development

Hormone related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS062001	Angiotensin Converting Enzyme Inhibitor	Glp-WPRPQIPP-OH (trifluoroacetate salt)	35115-60-7	\$55	≥ 95%
KS063002	Angiotensin II (human)	DRVYIHPF-OH (trifluoroacetate salt)	4474-91-3	\$49	≥ 95%
KS062003	Teriparatide acetate	SVSEIQLMHNLGKHLNSMERVE WLRKQLQDVHNF-OH	52232-67-4	\$280	≥ 95%
KS033001	Glucagon (human)	HSQGTFTSDYSKYLDSRRAQDF VQWLMNT-OH (trifluoroacetate salt)	16941-32-5	\$239	≥ 95%
KS061004	Oxytocin	CYIQNCPLG-NH2 (trifluoroacetate salt) (Cys1 and 6 bridge)	50-56-6	\$109	≥ 95%
KS061005	Luteinizing hormone-releasing factor (swine)	Glp-HWSYGLRPG-OH (trifluoroacetate salt)	35263-73-1	\$60	≥ 95%
KS062006	Angiotensin I Converting Enzyme Inhibitor 1	Glp-GLPPGPPIP-OH (trifluoroacetate salt)	30892-86-5	\$67	≥ 95%
KS042001	Somatostatin 14	AGCKNFFWKTFTSC-OH (Disulfide Bridge)	38916-34-6	\$164	≥ 95%
KS061007	Ghrelin (human)	GSS(palmitoyl)FLSPEHQKAQ QRKESKKPPAKLQPROH (trifluoroacetate salt)		\$286	≥ 95%
KS062008	Angiotensin I Converting Enzyme Inhibitor 3	RPGFSPFR-OH (trifluoroacetate salt)		\$49	≥ 95%
KS061009	Calcitonin (human)	CGNLSTCMLGTYTQDFNKFHTF PQTAIGVGAP-NH2 (trifluoroacetate salt) (Cys1 and 7 bridge)	21215-62-3	\$395	≥ 95%

◆ Peptide Drug Development

Hormone related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS061010	ACTH (1-39), human	SYSMEHFRWGKPVGKKRRP VKVYPNGAEDESAEAPLEF -OH	12279-41-3	\$321	≥95%
KS063011	Substance P	RPKPQQFFGLM-NH2 (trifluoroacetate salt)	33507-63-0	\$64	≥95%
KS061012	Antileukinate	Ac-RRWWCRNH2 (trifluoroacetate salt)	138559-60-1	\$36	≥95%
KS042002	Octreotide	fCFwKTCT-ol (Disulfide Bridge)	79517-01-4	\$164	≥95%
KS062013	Calcitonin Gene Related Peptide (human)	ACDTATCVTHRLAGLLSRSG GVVKNFVPTNVGSKAF- NH2 (Disulfide bridge)	90954-53-3	\$457	≥95%
KS062014	Calcitonin Gene Related Peptide II (human)	ACNTATCVTHRLAGLLSRSG GMVKS NFVPTNVGSKAFNH 2 (trifluoroacetate salt) (Cys2 and 7 bridge)	98824-26-1	\$457	≥95%
KS061015	Melanin Concentrating Hormone (human)	DFDMLRCMLGRVYRPCW QV-OH (trifluoroacetate salt) (Disulfide bond)	128315-56-0	\$335	≥95%
KS061016	aviptadil	HSDAVFTDNYTRLRKQMAV KKYLNSILN-NH2	40077-57-4	\$231	≥95%
KS061017	Luteinizing Hormone-Releasing Hormone Antagonist	Ac-D2Nal-f(4-Cl)- beta(3pyridyl)α-GRPα- NH2 (trifluoroacetate salt)	292141-31-2	\$195	≥95%
KS032005	Amylin (human)	KCNTATCATQRLANFLVHSS NNFGAILSSTNVGSNTY-OH (trifluoroacetate salt) (Cys2 and 7 bridge)	122384-88-7	\$366	≥95%
KS062018	ANP (1-28); Carperitide	SLRRSSCFGGRMDRIGASQ GLGCNSFRY-OH (Cys7 and 23 bridge)	89213-87-6	\$346	≥95%

◆ Peptide Drug Development

Hormone related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS042005	Peptide YY (human)	YPIKPEAPGEDASPEELNRYASLRHY LNLVTRQRY-NH2 (trifluoroacetate salt)	118997-30-1	\$297	≥95%
KS061019	Vasoactive intestinal peptide	HSDALFTDYTRLRKQMAMKKYLNSV LN-NH2 (trifluoroacetate salt)	96886-24-7	\$216	≥95%
KS061020	Orexin B (mouse)	RPGPPGLQGRLQRLQANGNHAA GILTM-NH2 (trifluoroacetate salt)	202801-92-1	\$231	≥95%
KS062021	Angiotensin III (human)	RVYIHPF-OH (trifluoroacetate salt)	100900-06-9	\$48	≥95%
KS061022	Calcitonin (rat)	CGNLSTCMLGTYTQDLNKFHTFPQTSI GVGAP-NH2 (trifluoroacetate salt) (Cys1 and 7 bridge)	11118-25-5	\$395	≥95%
KS042004	Peptide YY (canine, mouse, porcine, rat)	YPAKPEAPGEDASPEELSRYYASLRHY LNLVTRQRY-NH2 (trifluoroacetate salt)	81858-94-8	\$297	≥95%
KS061023	Orexin A (human)	Glp- PLPDCCRQKTCSCRLYELLHGAGNH AAGILTL-NH2 (trifluoroacetate salt) (Cys6 and 12 bridge, Cys7 and 14 bridge)	205640-90-0	\$1,087	≥95%
KS061024	Orexin B (human)	RSGPPGLQGRLQRLQASGNHAAG ILTM-NH2 (trifluoroacetate salt)	205640-91-1	\$231	≥95%
KS042006	Gastrin 1 (human)	GlpGPWLEEEEEAYGWMDF-NH2	10047-33-3	\$100	≥95%
KS062025	Calcitonin Gene Related Peptide (rat)	SCNTATCVTHRLAGLLSRSGGVVKD NFVPTNVGSEAF-NH2 (trifluoroacetate salt) (Cys2 and 7 bridge)	96827-03-1	\$408	≥95%
KS042007	Caerulein	Glp-QDY(SO3H)TGWMDF-NH2	17650-98-5	\$71	≥95%
KS061026	Egg Laying Hormone	ISINQDLKAITDMLLTEQIRERQRYLAD LRQRLLEK-NH2 (trifluoroacetate salt)	117680-39-4	\$297	≥95%

◆ Peptide Drug Development

Hormone related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS061027	Parathyroid Hormone (1-34) (rat)	AVSEIQLMHNLGKHLASVERMQWL RKKLQDVHNF-OH (trifluoroacetate salt)	98614-76-7	\$219	≥ 95%
KS061028	Gastrin Releasing Peptide (Porcine)	APVSVGGGTVLAKMYPRGNHWA VGHLM-NH2 (trifluoroacetate salt)	74815-57-9	\$222	≥ 95%
KS061029	GLP-2 (1-34) (human)	HADGSFSDEMNTILDNLAARDFINW LIQTKITDR-OH (trifluoroacetate salt)	99120-49-7	\$280	≥ 95%
KS061030	TRH (Human)	Pyr-HP-NH2 (trifluoroacetate salt)	24305-27-9	\$18	≥ 95%
KS061031	GTP-Binding Protein Fragment	CKQLQKDKQVYRATHR-OH (trifluoroacetate salt)	101038-78-2	\$97	≥ 95%
KS032008	GLP-2 (human)	HADGSFSDEMNTILDNLAARDFINW LIQTKITD-OH (trifluoroacetate salt)	223460-79-5	\$272	≥ 95%
KS061032	ACTH (1-13) (human)	SYSMEHFRWGKPV-OH (trifluoroacetate salt)	22006-64-0	\$91	≥ 95%
KS042009	Gastrin Releasing Peptide (human)	VPLPAGGGTVLTKMYPRGNHWAV GHLM-NH2 (trifluoroacetate salt)	93755-85-2	\$222	≥ 95%
KS042008	Secretin (porcine)	HSDGFTTSELSRLRDSARLQRLQGL V-NH2 (acetate salt)	17034-34-3	\$222	≥ 95%
KS061033	ACTH (1-39) (rat)	SYSMEHFRWGKPVGKKRRPVKVYP NVAENESAEAPLEF-OH (trifluoroacetate salt)	77465-10-2	\$321	≥ 95%
KS042012	Secretin (human)	HSDGFTTSELSRLREGARLQRLQGL V-NH2 (trifluoroacetate salt)	108153-74-8	\$222	≥ 95%
KS061034	Cosyntropin	SYSMEHFRWGKPVGKKRRPVKVYP- OH	16960-16-0	\$146	≥ 95%

◆ Peptide Drug Development

Hormone related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS042011	DOTA-[Tyr3]-Octreotide	DOTA-fCYwKTCT-ol (trifluoroacetate salt) (Cys2 and 7 bridge)	177943-89-4	\$528	≥95%
KS042013	Insulin B (13 – 23)	EALYLVCGERG-OH (ammonium salt)		\$87	≥95%
KS032012	Amylin (rat)	KCNTATCATQRLANFLVRSSNNL GPVLPPTNVGSNTY-NH2 (trifluoroacetate salt) (Cys2 and 7 bridge)	124447-81-0	\$457	≥95%
KS042014	Motilin (human, Porcine)	FVPIFITYGELQRMQEKERKNGQ-OH (trifluoroacetate salt)	9072-41-7	\$129	≥95%
KS061035	beta-MSH(Monkey)	DEGPYRMEHFRWGSPPKD-OH (trifluoroacetate salt)	17750-75-3	\$211	≥95%
KS061036	alpha-Mating Factor Pheromone	WHWLQLKPGQPMY-OH (trifluoroacetate salt)	59401-28-4	\$77	≥95%
KS061037	Allatostatin I	APSGAQRLYGFGI-NH2 (trifluoroacetate salt)	123338-10-3	\$77	≥95%
KS032002	GLP-1 (1-37) (human)	HDEFERHAEGTFTSDVSSYLEGQA AKEFIAWLVKGRG-OH (trifluoroacetate salt)	87805-34-3	\$304	≥95%
KS032010	GLP-1 (1-36) amide (human)	HDEFERHAEGTFTSDVSSYLEGQA AKEFIAWLVKGR-NH2 (trifluoroacetate salt)	99658-04-5	\$297	≥95%
KS063038	Renin Substrate Tetradecapeptide (rat)	DRVYIHPFHLLYYS-OH (trifluoroacetate salt)	110200-37-8	\$231	≥95%
KS061039	Calcitonin (salmon)	CSNLSTCVLGKLSQELHKLQTYPR TNTGSGTP-NH2 (Cys1 and 7 bridge)	47931-85-1	\$219	≥95%
KS061040	Neurokinin A (Porcine)	HKTDSFVGLM-NH2 (trifluoroacetate salt)	86933-74-6	\$59	≥95%
KS061041	Pancreatic Polypeptide (rat)	APLEPMYPGDYATHEQRAQYETQ LRRYINTLRPRY-NH2 (trifluoroacetate salt)	90419-12-8	\$164	≥95%

◆ Peptide Drug Development

Cardiovascular Disease related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS063002	Angiotensin II (human)	DRVYIHPF-OH (trifluoroacetate salt)	4474-91-3	\$49	≥95%
KS062001	Angiotensin Converting Enzyme Inhibitor	GlpTrpProArgProGlnIleProProOH (trifluoroacetate salt)	35115-60-7	\$55	≥95%
KS091001	Angiotensin I Converting Enzyme Inhibitor 2	Glp-GLPPGPIPP-OH (trifluoroacetate salt)		\$67	≥95%
KS062006	Angiotensin I Converting Enzyme Inhibitor 1	Glp-GLPPRPKIPP-OH (trifluoroacetate salt)	30892-86-5	\$67	≥95%
KS062008	Angiotensin I Converting Enzyme Inhibitor 3	RPGFSPFR-OH (trifluoroacetate salt)		\$67	≥95%
KS062013	Calcitonin Gene Related Peptide (human)	ACDTATCVTHRLAGLLSRSGGVK NNFVPTNVGSKAF-NH2 (Disulfide bridge)	90954-53-3	\$457	≥95%
KS062025	Calcitonin Gene Related Peptide (rat)	SCNTATCVTHRLAGLLSRSGGVK DNFVPTNVGSEAF-NH2 (trifluoroacetate salt) (Cys2 and 7 bridge)	96827-03-1	\$408	≥95%
KS062014	Calcitonin Gene Related Peptide II (human)	ACNTATCVTHRLAGLLSRSGGMVK SNFVPTNVGSKAF-NH2 (trifluoroacetate salt) (Cys2 and 7 bridge)	98824-26-1	\$457	≥95%
KS091002	Endothelin-1	CSCSSLMDKECVYFCHLDIIW-OH (ammonium acetate salt) (Cys1 and 15 bridge, Cys3 and 11 bridge)	117399-94-7	\$370	≥95%
KS091003	Bradykinin	RPPGFSPFR-OH (trifluoroacetate salt)		\$55	≥95%
KS062021	Angiotensin III (human)	RVYIHPF-OH (trifluoroacetate salt)	100900-06-9	\$48	≥95%
KS092004	Angiotensin I (human)	DRVYIHPFHL-OH (trifluoroacetate salt)	70937-97-2	\$58	≥95%

◆ Peptide Drug Development

Cardiovascular Disease related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS062018	ANP (1-28); Carpenterite	SLRRSSCFGGRMDRIGAQSGLGC NSFRY-OH (Cys7 and 23 bridge)	89213-87-6	\$346	≥95%
KS063038	Renin Substrate Tetradecapeptide (rat)	DRVYIHPFLLLYS-OH (trifluoroacetate salt)	110200-37-8	\$231	≥95%
KS091005	Adrenomedullin (1- 52) (human)	YRQSMNNFQGLRSFGCRFGTCTV QKLAHQIQFTDKDKDNVAPRSKIS PQGY-NH2 (trifluoroacetate salt) (Cys16 and 21 bridge)	148498-78-6	\$765	≥95%
KS091006	Adrenomedullin (1- 52) (porcine)	YRQSMNNFQGLRSFGCRFGTCTV QKLAHQIQFTDKDKDGVAPRSKIS PQGY-NH2 (trifluoroacetate salt) (Cys16 and 21 bridge)	912862-96-5	\$1,146	≥95%
KS091007	Copeptin (human)	ASDRSNATQLDGPAGALLRLVQL AGAPEPFEPAPDAY-OH (trifluoroacetate salt)	78362-34-2	\$321	≥95%
KS091008	Intermedin (human)	TQAQLLRVGCVLGTCQVQNLSHRL WQLMGPAQRQDSAPVDPSSPHSY -NH2 (trifluoroacetate salt) (Disulfide bond Cys10 and Cys15)	1188922-20- 4	\$749	≥95%
KS091009	Intermedin (rat)	PHAQLLRVGCVLGTCQVQNLSHRL WQLVRPSGRRDSAPVDPSSPHSY- NH2 (trifluoroacetate salt) (Disulfide bond Cys10 and Cys15)	1816940-00- 7	\$749	≥95%
KS084006	Angiotensin I/II (1-7)	DRVYIHP-OH (trifluoroacetate salt)	51833-78-4	\$42	≥95%
KS063038	Rat Renin Inhibitor Peptide	Ac-HPFVStalF-NH2 (trifluoroacetate salt)	110200-37-8	\$231	≥95%
KS091010	Renin Inhibitor III	RRPFHStalHK-OH (trifluoroacetate salt)		\$79	≥95%
KS091011	Hoe 140	rRP-Hyp-G-thi-S-Dtic-Oic-R-OH	130308-48-4	\$133	≥95%
KS091012	Urotensin II (goby)	AGTADCFWKYCV-OH (trifluoroacetate salt) (Cys6 and 11 bridge)	9047-55-6	\$146	≥95%
KS091013	Urotensin II (human)	ETPDCFWKYCV-OH (trifluoroacetate salt) (Cys5 and 10 bridge)	251293-28-4	\$67	≥95%

◆ Peptide Drug Development

SARS-CoV-2 related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS092004	Angiotensin I (human)	DRVYIHPFHL-OH (trifluoroacetate salt)	70937-97-2	\$58	≥95%
KS063002	Angiotensin II (human)	DRVYIHPF-OH (trifluoroacetate salt)	4474-91-3	\$49	≥95%
KS022003	Fusion Inhibitory Peptide	Z-fFG-OH	75539-79-6	\$40	≥95%
KS084006	Angiotensin I/II (1-7)	DRVYIHP-OH (trifluoroacetate salt)	51833-78-4	\$42	≥95%

Hematology related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS052001	Thrombin substrate	5FAM- GGfPRSGGGK(CPQ2)KPEG 2-Cys-OH (trifluoroacetate salt)		\$807	≥95%
KS051002	Tryptophan Motif Peptide	GGWSHW-NH2 (trifluoroacetate salt)		\$36	≥95%
KS052003	Thrombin Sensitive Peptide	azidoacety- AK(5FAM)GALVPRGSAGK(C PQ2)-NH2 (ammonium salt)		\$807	≥95%
KS051004	PAR-1 Agonist peptide	TFLLRN-OH (trifluoroacetate salt)		\$36	≥95%
KS051005	thrombin receptor Atagonist	MSRPACPNDKYE-OH (trifluoroacetate salt)	207553-92- 2	\$71	≥95%
KS051006	PAR-2 amide (1-6)	SLIGKV-NH2 (trifluoroacetate salt)	190383-13- 2	\$36	≥95%
KS051007	Alpha-2 Plasmin Inhibitor; Serpin Peptidase Inhibitor	NQEQVSP-OH (trifluoroacetate salt)		\$42	≥95%

◆ Peptide Drug Development

Cell apoptosis related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS071001	Caspase-3 Inhibitor I	AcAAVALLPAVLLALLAPDEVD-CHO		\$277	≥95%
KS071002	FITC-C6-Tyr-Val-Ala-Asp-Ala-Pro-Lys(DNP)	FITC-C6-YVADAPK(DNP)-OH		\$233	≥95%
KS071003	Caspase Inhibitor II	Ac-AAVALLPAVLLALLAPVAD-CHO		\$277	≥95%
KS071004	Calcium Like Peptide 3	VKFGVGFK-OH (trifluoroacetate salt)	261969-05-5	\$86	≥95%
KS071005	Caspase-8 Inhibitor I	Ac-AAVALLPAVLLALLAPIETD-CHO	886462-83-5	\$277	≥95%
KS071006	Caspase-8 Inhibitor	Ac-IEPD-CHO	210344-98-2	\$182	≥95%
KS071007	GSK-3 beta Peptide Inhibitor	Myr-GKEAPPAPPQS(PO3H2)P-NH2 (trifluoroacetate salt)		\$150	≥95%
KS071008	Apopain Substrate	Ac-DEVD-AMC	169332-61-0	\$159	≥95%
KS071009	Caspase-1 Inhibitor I	Ac-AAVALLPAVLLALLAPYVAD-CHO	201608-12-0	\$277	≥95%

Inflammation related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS084006	Angiotensin I/II (1-7)	DRVYIHP-OH (trifluoroacetate salt)	51833-78-4	\$42	≥95%
KS063011	Substance P	RPKPQQFFGLM-NH2 (trifluoroacetate salt)	33507-63-0	\$64	≥95%
KS141001	Fibronectin-Binding Protein	FNKHTEIIEEDTNKDKPSYQFG GHNSVDFEEDTLPKV-OH (trifluoroacetate salt)	119977-20-7	\$313	≥95%
KS141002	biotin labeled Steroid Receptor Coactivator-1 (SRC-1)	Biotin-CPSSHSLTERHKILHRLQEG SPS-OH (trifluoroacetate salt)		\$208	≥95%

◆ Peptide Drug Development

Cancer treatment related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS081001	MMP Inhibitor 1	abz-GPDL _a NH-OH (trifluoroacetate salt)	124168-73-6	\$46	≥95%
KS081002	Cyclo (-RADfE)	Cyclo(RADfE) (ammonium salt)		\$91	≥95%
KS081003	Integrin Binding Peptide	Ac-GCGYGRGDSPG-NH ₂ (trifluoroacetate salt)	278792-07-7	\$67	≥95%
KS081004	MG-132	ZLLLCHO	133407-82-6	\$86	≥95%
KS082005	Fluorogenic MMP Substrate	DNPPLGLWAr-NH ₂ (trifluoroacetate salt)	121282-17-5	\$170	≥95%
KS084006	Angiotensin I/II (1-7)	DRVYIHP-OH (trifluoroacetate salt)	51833-78-4	\$42	≥95%
KS081007	Kisspeptin-10, Kiss1 (fish)	YNLNSFGLRY-NH ₂ (trifluoroacetate salt)		\$61	≥95%
KS081008	Kisspeptin-10, Kiss2 (fish, frog)	FNFNPFGLRF-NH ₂ (trifluoroacetate salt)		\$61	
KS081009	Calpain Substrate	E(EDANS)PLFAERK(Dabcyl)-OH (trifluoroacetate salt)		\$222	≥95%

◆ Peptide Drug Development

Protein kinase & phosphatase related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS111001	Substrate for Tyrosine Protein Kinase	RRLIEDNEYTARG-OH (trifluoroacetate salt)	81493-98-3	\$77	≥95%
KS111002	Melittin	GIGAVLKVLTTGLPALISWIKR KRQQ-NH2 (trifluoroacetate salt)	20449-79-0	\$214	≥95%
KS111003	5-Fam-Woodtide	5FAM-KKISGRSLPIMTEQ-NH2 (trifluoroacetate salt)	1566528-51-5	\$143	≥95%
KS111004	Pannexin-1; Panx1	WRQAAFVDSY-OH (trifluoroacetate salt)		\$58	≥95%
KS111005	CHK1 and CHK2 Substrate	KKKVSRSGLYRS(PO3H2)PS MPENLNRPR-NH2 (trifluoroacetate salt)		\$196	≥95%

Other peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS151001	Human Histone H3	ARTKQTARKSTGGKAPRKQL C-OH (trifluoroacetate salt)		\$123	≥95%
KS151002	Human Histone H4	AGGKGGKGMGKVGAKR HS-OH (trifluoroacetate salt)		\$142	≥95%
KS151003	Histone H3 Peptide	Ac-QTARKSTGGKAPRKQLATK-NH2 (trifluoroacetate salt)		\$111	≥95%
KS151004	IFN-gamma Antagonist	AYC(Acm)RDGKIGPPKLDI RKEEKQI-OH (trifluoroacetate salt)	158040-83-6	\$129	≥95%
KS151005	Ac-RGK(Ac)-AMC	Ac-RGK(Ac)-AMC (trifluoroacetate salt)	660846-97-9	\$118	≥95%
KS151006	Ac-Gly-Ala-Lys(Ac)-AMC	Ac-GAK(Ac)-AMC	577969-56-3	\$118	≥95%
KS151007	Peptide Standard 1 for amino acid analysis	CPDFGHIAMELSVRTWKY-OH (trifluoroacetate salt)		\$106	≥95%

◆ Peptide Drug Development

Fluorescence resonance energy transfer substrates

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS022004	Malaria Aspartyl Proteinase FRET Substrate (Dabcyl-Edans pair)	DABCYL-ER-Nle-FLSFP-EDANS (trifluoroacetate salt)	263718-22-5	\$255	≥ 95%
KS082005	Fluorogenic MMP Substrate	DNPPLGLWAr-NH ₂ (trifluoroacetate salt)	121282-17-5	\$170	≥ 95%
KS012004	β-Secretase Substrate I (MCA-DNP pair)	MCA-EVKMDAEFK(DNP)-NH ₂ (ammonium acetate salt)		\$219	≥ 95%
KS052001	Thrombin substrate	5FAM-GGfPRSGGGK(CPQ2)K-PEG2-Cys-OH (trifluoroacetate salt)		\$807	≥ 95%
KS012005	α-Secretase Substrate I (MCA-DNP pair)	MCA-HQKLVFFAK(DNP)-NH ₂ (trifluoroacetate salt)		\$219	≥ 95%
KS121001	Fluorogenic MMP-2 Substrate	MCA-PLA-Nva-Dap(DNP)AR-NH ₂ (trifluoroacetate salt)	256394-92-0	\$219	≥ 95%
KS052003	Thrombin Sensitive Peptide	azidoacetyl-AK(5FAM)GALVPRGSA GK(CPQ2)-NH ₂ (ammonium salt)		\$807	≥ 95%
KS121002	Calpain Substrate	E(EDANS)PLFAERK(Dabcyl)-OH (trifluoroacetate salt)	1914987-47-5	\$255	≥ 95%

Immunomodulation

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS131001	Pam3CSK4	PalmitoylCys((RS)2,3di(palmitoyloxy)propyl)SKKKK-OH (trifluoroacetate salt)	112208-00-1	\$231	≥ 95%
KS131002	Thymosin Alpha 1	Ac-SDAAVDTSSSEITTKDLKEKKEVV EEAEN-OH	62304-98-7	\$231	≥ 95%
KS131003	L-Selectin Peptide	CQKLDKSFMSIK-OH (trifluoroacetate salt)		\$71	≥ 95%

◆ Peptide Drug Development

Enzyme inhibitors

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS181004	Bradykinin (Human, Bovine, Rat, Mouse)	RPPGFSPFR	58-82-2	\$28	≥ 95%
KS181005	CCK-33 (Porcine)	KAPSGRVSMIKNLQSLDPSHRISDRDY(SO3H)MGWMDF-NH2	67256-27-3	\$160	≥ 95%
KS181016	PED-3788-PI	N-cis-2,6-Dimethylpiperidinocarbonyl-L-γ-Me-Leu-D-Trp(COOCH3)-D-Nle (Sodium Salt)	103900-19-2	\$1,103	≥ 95%
KS181017	Fructose-1,6-Bisphosphatase 1, human, recombinant	MADQAPFDTDVNTLRFVMEEGRKARGT GELTQLLSLCTAVKAISSAVRKAGIAHLY GIA GSTNVTGDQVKKLDVLSNDLVMNML KSSFATCVLVSEEDKHAIIVEPEKRGKYVVC FDPLDGSSNIDCLVSVGTIFGIYRKKSTDEPS EKDALQPGRNLVAAAGYALYGSATMLVLA MDCGVNCFMLDPAIGEFILVDKDVKIKKK GKIYSLNEGYARDFDPAVTEYIQRKKFPPD NSAPYGARYVGS MVADVHRTL VYGGIFL YPANKKSPNGKLRLLYECNPMAYVMEKA GGMATTGKEAVLDVIPTDIHQ RAPVILGSP DDVLEFLKVYEKHS AQ		\$25,066	≥ 95%
KS181018	IL 21 (Mouse)	MERTLVCLVVI FLGTVAHKSSPQ GPDRLLIR LRHLIDIVEQLKIYENDLDPELLSAPQDVKG HCEHA AFACFQKAKLKPSNP GNNKTFIIDL VAQLRRRLPARRGGKKQKHI AKCPSCDSY EK RTPKEFLERLKWLLQKMIHQHLS		\$14,207	≥ 95%
KS181019	TFF1 (Human)	MATMENKVICALVLV SMLALGTLAE AQTE TCTVAPRERQNCGFP GVTPSQCANKGC CFDDTVR GVPWCFYPNTIDV PPEEECEF		\$4,386	≥ 95%
KS181020	β-Defensin-2 (human)		372146-20-8	\$46,778	≥ 95%
KS181022	CNP-53 (Human)	DLRVDTKSRAAWARLLQEHPNARKYKGA NKKGLSKGCFGLKLD RIGSMSGLGC-OH	141294-77-1	\$458	≥ 95%
KS181024	Protease-Activated Receptor 1 (PAR1) Antagonist	3Mercaptopropionyl-Fcha-Cha-RKPNDK-NH2		\$28	≥ 95%
KS181025	β-Defensin-1 (human)	DHYN CVSSGGQCLYSACPIFTKI QGTCYR GKAKCCK-OH		\$228	≥ 95%
KS181026	Decorsin	APRLPQCQGDDQE KCLCNKDECPPGQ CRFPRGDADPYCE-OH		\$247	≥ 95%

◆ Peptide Drug Development

RGD related peptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS033001	Glucagon (human)	HSQGTFTSDYSKYLDSRRAQDFVQ WLMNT-OH	16941-32-5	\$140	≥95%
KS191001	ENZ-297	MPLGLLWLGLALLGALHAQAQD STSDLIPAPPLSKVPLQQNFQDNQ FQGKWWYVVGLAGNAILREDKDP QKMYATIYELKEDKSYNVTSVLFRKK KCDYWIRTFVPGCQPGFTLGNIK SYPGLTSYLVRVVSTNYNQHAMVF FKKVSQNREYFKITLYGRKELTSELK ENFIRFSKSLGLPENHIVFPVPIDQCI DG		\$780	≥95%
KS191002	IKK-4374-V	KKKLRRQEAFDAY	209005-05-0	\$45	≥95%
KS191003	Arphamenine B	4Fluorobenzoyl-RR-Nal-CY-Cit- KkPyRCit-CR-NH ₂ (Disulfide)		\$137	≥95%
KS191004	Z-VAD(OMe)-FMK	Z-V-AD(OMe)-CH ₂ F	187389-52-2	\$93	≥95%
KS191006	DABCYL-Lys- HCoV-SARS	Dabcyl- KTSAVLQSGFRKME(Edans)-NH ₂	730985-86- 1	\$212	≥95%
KS191007	Diprotin A	IPI		\$21	≥95%
KS191008	Thymosin-b ₄	AcSDKPDMAEIEKFDKSKLKKTETQ EKNPLPSKETIEQEKGAGE-OH		\$261	≥95%
KS191009	IDE Inhibitor 6bK	(Fumaryl-Lys-Cha-D-Bpa)-Lys- NH ₂		\$60	≥95%

◆ Peptide Drug Development

Neuropeptides

Cat. No.	Product Name	Sequence	CAS NO.	Price / 1 mg	Purity
KS171001	Neuropeptide S	SFRNGVGTGMKKTsfQRAKS-OH	412938-67-1	\$135	≥95%
KS063011	Substance P	RPKPQQFFGLM-NH2 (trifluoroacetate salt)	33507-63-0	\$64	≥95%
KS171002	Neuropeptide Y	YPSKPDNPGEDAPAEDMARYY SALRHYINLITRQRY-NH2 (trifluoroacetate salt)	90880-35-6	\$313	≥95%
KS171003	Neurotensin	Glp-LYENKPRRPYIL-OH (trifluoroacetate salt)	55508-42-4	\$107	≥95%
KS171004	Pro-Cortistatin (28-47)	SALPLESGPTGQDSVQDATG-NH2 (trifluoroacetate salt)		\$117	≥95%
KS171005	Neurokinin B	DMHDFVGLM-NH2 (trifluoroacetate salt)	86933-75-7	\$58	≥95%
KS171006	Urocortin (human)	DNPSLSIDLTFHLLRTLLELARTQS QRERAeqnRIIFDSV-NH2 (trifluoroacetate salt)	176591-49-4	\$373	≥95%
KS171007	Urocortin (rat)	DDPPLSIDLTFHLLRTLLELARTQS QRERAeqnRIIFDSV-NH2 (trifluoroacetate salt)	171543-83-2	\$373	≥95%
KS171008	Pro-Cortistatin (51-81)	TGLLTFLAWWHEWASQDSSSTA FEGGTPELS-OH (trifluoroacetate salt)		\$257	≥95%
KS171009	Urocortin II (mouse)	VILSLDVPIGLLRILLEQARYKAAR NQAATNAQILAHV-NH2 (trifluoroacetate salt)	330648-32-3	\$313	≥95%
KS171010	Urocortin III (human)	FTLSLDVPTNIMNLLFNIAKAKNLR AQAAAANAHLMAQI-NH2 (trifluoroacetate salt)	357952-09-1	\$313	≥95%
KS171011	Urocortin III (mouse)	FTLSLDVPTNIMNIFNIDKAKNLR AKAAAANAQLMAQI-OH (trifluoroacetate salt)	357952-10-4	\$313	≥95%
KS171012	FMRF	FMRF-OH (trifluoroacetate salt)	74012-06-9	\$26	≥95%
KS171013	Neuromedin U (rat)	YKVNEYQGPVAPSGGFFLRPR N-NH2 (trifluoroacetate salt)	117505-80-3	\$135	≥95%

Quotations and Ordering

www.ks-vpeptide.com

KS-V Peptide

Address:

Building A2, National Health Big Data
Industrial Park, Hefei, Anhui, China

Email:

services@ks-vpeptide.com
sales@ks-vpeptide.com



KS-V PEPTIDE
The Peptide Experts



Welcome to the website for detailed browsing
www.ks-vpeptide.com

***Innovation To Help Drug Research And Development
Cooperation To Promote Healthy Life***